Adimab, LLC has entered a multi-target discovery and optimization collaboration with Sanofi and will use its platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize any resulting therapeutic antibodies and bispecifics. Adimab will receive an undisclosed upfront payment, research fees and technical milestones. Also, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during th...